Specify a stock or a cryptocurrency in the search bar to get a summary
Femasys Inc
FEMYFemasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia. Address: 3950 Johns Creek Court, Suwanee, GA, United States, 30024
Analytics
WallStreet Target Price
8.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures FEMY
Dividend Analytics FEMY
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History FEMY
Stock Valuation FEMY
Financials FEMY
Results | 2019 | Dynamics |